Diabetes (Type 2)
Incretin-class agents (GLP-1, dual GIP/GLP-1, triple agonists) and amylin analogues have the strongest human RCT evidence for glycemic control and cardiometabolic risk. Standard care remains first-line; this page is a reference, not a recommendation.
Why certain peptides surface — weighted by clinical relevance.
Cardiometabolic health
weight 1.00Core outcome: glycemic control and cardiometabolic risk reduction is the primary axis for type 2 diabetes management.
Weight / fat reduction
weight 0.90Weight loss of 5–15% materially improves insulin sensitivity and HbA1c; incretins drive both.
Appetite & food-noise suppression
weight 0.70Reduced food noise and lower caloric intake are the mechanistic lever behind GLP-1 / dual / triple agonist benefit.
Outcome × ingredient signal — backed by indexed studies.
Each cell shows the clinical signal status and the count of indexed studies for that ingredient × outcome pair. Click any cell to open the ingredient brief.
| Outcome \ Ingredient | Semaglutide | Tirzepatide | Retatrutide | Cagrilintide | Tesamorelin |
|---|---|---|---|---|---|
| Cardiometabolic health | ·— | ·— | ·— | ·— | ·— |
| Weight / fat reduction | 4moderate | ·— | ·— | ·— | — |
| Appetite & food-noise suppression | ·— | ·— | ·— | ·— | — |
Matched protocol templates for this condition.
Matching templates…
What cohorts have used — and at what tier of evidence.
- SemaglutideGLP-1 receptor agonist0.25–2.4 mg/week, titratedAnecdotal→
- TirzepatideGIP / GLP-1 dual agonist2.5–15 mg/week, titratedAnecdotal→
- RetatrutideGIP / GLP-1 / glucagon triple agonist1–12 mg/week (trial)Anecdotal→
- CagrilintideAmylin analogue0.16–2.4 mg/week (trial)Anecdotal→
- LiraglutideGLP-1 receptor agonist0.6–3.0 mg/dayAnecdotal→
Suggestive, never prescriptive. MyDosage does not recommend a dose, a substance or a protocol. Decisions belong with you and a clinician.